MoonLake Investors Notified of SDNY Securities Suit as Dec. 15 Lead‑Plaintiff Deadline Nears
The case stems from a near 90% share-price collapse after sonelokimab’s Phase 3 results underwhelmed and failed to top a rival therapy, with complaints alleging investors were misled about supposed Nanobody advantages.
Overview
- At least one putative class action is pending in the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612, asserting claims under Sections 10(b) and 20(a) of the Exchange Act.
- Law firms Bleichmar Fonti & Auld, Glancy Prongay & Murray, and Rosen Law Firm are soliciting class members and highlighting a December 15, 2025 deadline to seek appointment as lead plaintiff.
- The putative class period spans March 10, 2024 through September 29, 2025 for purchasers of MoonLake common stock.
- Complaints allege MoonLake misrepresented sonelokimab’s differentiation, including claims that SLK and BIMZELX target the same cytokines IL‑17A and IL‑17F and that the Nanobody structure would not yield superior clinical benefit or efficacy from tissue penetration.
- The suits follow MoonLake’s September 28, 2025 Phase 3 VELA update, including VELA‑2 missing its primary endpoint and SLK failing to match bimekizumab, after which the stock fell from $61.99 to $6.24 on September 29, 2025; no class has been certified at this stage.